How were Principia Biopharma's earnings last quarter?

Principia Biopharma Inc. (NASDAQ:PRNB) announced its earnings results on Thursday, August, 6th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.03) by $1.34. The company had revenue of $50 million for the quarter, compared to analyst estimates of $50 million.

What other stocks do shareholders of Principia Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include Pfizer (PFE) , AbbVie (ABBV) , Advanced Micro Devices (AMD) , Cisco Systems (CSCO) , Gilead Sciences (GILD) , Micron Technology (MU) , QUALCOMM (QCOM) , VBI Vaccines (VBIV) , ImmunoGen (IMGN) and Taiwan Semiconductor Manufacturing (TSM) .

When did Principia Biopharma IPO?

Principia Biopharma (PRNB) raised $75 million in an initial public offering (IPO) on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

NASDAQ:PRNB

Principia Biopharma (PRNB) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free PRNB Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $100.05
▼
$100.05
50-Day Range: $99.95
▼
$100.27
52-Week Range: $25.35
▼
$101.89

Volume: N/A
Average Volume: 729,676 shs
Market Capitalization: $3.32 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Principia Biopharma alerts:

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Principia Biopharma Stock (NASDAQ:PRNB)

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

PRNB Stock News Headlines

May 28, 2023 | bizjournals.com

Principia College names new president

May 5, 2023 | theguardian.com

CBI appoints ethics consultancy Principia Advisory in fight for survival

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 22, 2023 | benzinga.com

Truist Securities Downgrades 9 Meters Biopharma to Hold, Announces $38 Price Target

January 17, 2023 | msn.com

Wooly mammoth tusk discovered on Principia College campus

October 12, 2022 | finance.yahoo.com

Dodge Construction Network Acquires Principia Consulting, Expanding Dodge Advisory Services’ Capabilities

October 1, 2022 | sfgate.com

Principia earns top US News & World Report rating

July 7, 2022 | investing.com

Principia Biopharma Inc (PRNB)

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

April 5, 2022 | chron.com

Dance therapy: In-person performances back at Principia

March 18, 2022 | msn.com

Where to find the Golden Order Principia in Elden Ring

January 10, 2022 | news.yahoo.com

Lebanon's Skobel signs with Principia

October 1, 2021 | chron.com

Principia College earns honors

July 31, 2021 | nasdaq.com

Principia Biopharma Inc. Common Stock (PRNB)

See More Headlines

Receive PRNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Principia Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/06/2020
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PRNB
CUSIP: N/A
CIK: N/A
Web: www.principiabio.com
Phone: 650-416-7700
Fax: N/A
Employees: 65
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-53,790,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -23.08%
Return on Assets: -21.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.01
Quick Ratio: 17.01

Sales & Book Value

Annual Sales: $35.16 million
Price / Sales: 94.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.95 per share
Price / Book: 9.14

Miscellaneous

Outstanding Shares: 33,209,000
Free Float: N/A
Market Cap: $3.32 billion
Optionable: Not Optionable
Beta: 0.86

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Alan B. Colowick Ph.D. (Age 57)
M.D., M.P.H., Exec. Chairman
Mr. Martin Babler (Age 54)
CEO & Director
Mr. Christopher Y. Chai (Age 52)
Chief Financial Officer
Ms. Stefani A. Wolff (Age 57)
Chief Devel. Officer
Dr. David M. Goldstein (Age 53)
Chief Scientific Officer

Key Competitors

View All Competitors

PRNB Stock Analysis - Frequently Asked Questions

How were Principia Biopharma's earnings last quarter?: Principia Biopharma Inc. (NASDAQ:PRNB) announced its earnings results on Thursday, August, 6th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.03) by $1.34. The company had revenue of $50 million for the quarter, compared to analyst estimates of $50 million.
What other stocks do shareholders of Principia Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Gilead Sciences (GILD), Micron Technology (MU), QUALCOMM (QCOM), VBI Vaccines (VBIV), ImmunoGen (IMGN) and Taiwan Semiconductor Manufacturing (TSM).
When did Principia Biopharma IPO?: Principia Biopharma (PRNB) raised $75 million in an initial public offering (IPO) on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

This page (NASDAQ:PRNB) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Principia Biopharma (PRNB) Stock Price, News & Analysis

About Principia Biopharma Stock (NASDAQ:PRNB)

PRNB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

PRNB Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info